Global Pediatric Vaccine Market Research Report 2021: Market is Expected to Reach $49.9 Billion in 2025

DUBLIN, Aug. 6, 2021 /PRNewswire/ — The report “Pediatric Vaccine Global Market Report 2021: COVID-19 Growth and Change to 2030” has been added to’s offering.

Logo for research and markets

Pediatric Vaccine Global Market Report 2021: COVID-19 Growth and Change through 2030 provides strategists, marketers, and senior management with the critical information they need to assess the global pediatric vaccine market.

Major players in the pediatric vaccine market include GlaxoSmithKline plc, Pfizer Inc., Sanofi SA, Merck & Co., Inc., Indian Immunologicals Limited, AstraZeneca plc, CSL Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd. and Panacea Biotec Ltd.

The global pediatric vaccine market is expected to grow from $28.97 billion in 2020 to $32.44 billion in 2021 at a compound annual growth rate (CAGR) of 12%.

The growth is mainly due to the companies resuming operations and adjusting to the new normal, while recovering from the COVID-19 impact, which had previously led to restrictive containment measures related to social distancing, operating on distance and the closure of commercial activities resulting in operational challenges.

The market is expected to reach $49.9 billion by 2025 at a CAGR of 11.4%.

The pediatric vaccine market consists of the sale of pediatric vaccines and associated services used to provide infants and children with immunity to specific diseases. The pediatric vaccine is a preparation of killed microorganisms, live attenuated organisms or live fully virulent organisms that are administered to stimulate the production of antibodies and provide immunity against one or more diseases in children. Pediatric vaccines are used in childhood immunization schemes to boost a child’s immunity or prevent diseases such as diphtheria, tetanus, whooping cough, flu, hepatitis B, polio, and many other infectious and non-infectious diseases.

Vaccine refusal by parents for their children is a prevailing tradition in many countries. Among the reasons for withholding children from vaccination are lack of knowledge, religious and philosophical objections, exaggerated concerns about vaccine safety, and others. According to a nationwide survey, more than half (51%) of pediatric services in the United States have policies in place to fire families who refuse childhood vaccines.

Demand for new vaccines is steadily growing to provide better immunization against challenging infectious diseases (eg tuberculosis, HIV/AIDS) and non-communicable chronic diseases such as cancer and neurodegenerative diseases. Novel approaches to vaccine development include structural immunogenic design, gene-based vaccine platforms, and effective adjuvant-recombinant antigen formulations.

Story continues

To meet the increasing demand for new vaccines, there is an ongoing search for pediatric vaccine manufacturers and developers to innovate vaccine design and manufacturing technologies. In January 2020, for example, Hilleman Laboratories, a global research and development organization, announced their plans to develop a new vaccine against Group B Streptococcus, a leading cause of neonatal infections in women, in the areas of maternal health and children.

The rising prevalence of chronic diseases such as tuberculosis, diphtheria and pneumonia in the age group of 15 years and younger will contribute to the growth of the pediatric vaccine market. The risk of serious disease outcomes and complications of infectious diseases increases in children and adolescents with chronic conditions.

The increased prevalence of chronic diseases in children increases the demand for immunization against chronic diseases, thereby fueling the growth of the pediatric vaccine market.

Main topics covered:

1. Summary

2. Market Characteristics for Pediatric Vaccines

3. Market Trends and Strategies for Pediatric Vaccines

4. Impact of COVID-19 on Pediatric Vaccines

5. Market Size and Growth for Pediatric Vaccines
5.1. Global Historic Pediatric Vaccine Market, 2015-2020, $Billion
5.1.1. Market drivers
5.1.2. Restrictions on the market
5.2. Global Forecasting Market for Pediatric Vaccines, 2020-2025F, 2030F, $Billion
5.2.1. Market drivers
5.2.2. Restrictions on the market

6. Market Segmentation for Pediatric Vaccines
6.1. Global Pediatric Vaccine Market, Segmentation by Vaccine Type, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

6.2. Global Pediatric Vaccine Market, Segmentation by Technology, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Live attenuated




Other technologies

6.3. Global Pediatric Vaccines Market Segmentation by Application, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Infectious disease



7. Pediatric Vaccines Market Analysis by Regions and Country
7.1. Global Pediatric Vaccine Market Split by Regions, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, USD Billion
7.2. Global Pediatric Vaccine Market Breakdown by Country, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Named companies

GlaxoSmithKline plc

Pfizer Inc.

Sanofi SA

Merck & Co., Inc.

Indian Immunologicals Limited

AstraZeneca plc

CSL Limited

Mitsubishi Tanabe Pharma Corporation

Serum Institute of India Pvt. Ltd.

Panacea Biotec Ltd.

Zydus Cadila




Abbott Laboratories

Eli Lillyand Company

F. Hoffmann-La Roche Ltd.

Novo Nordisk A / S

VF Corporation

Sinovac Biotech Ltd.


Sun Pharmaceutical Industries Ltd

Sellas and Takeda Pharmaceutical Company Limited

Daiichi Sankyo

For more information on this report, please visit

Media contact:

Research and markets
Laura Wood, senior manager

For EST business hours, call +1-917-300-0470
For USA/CAN Toll Free Call +1-800-526-8630
For GMT office hours, please call +353-1-416-8900

US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716


View Original Content: 2025—long-term forecast-to-2030–301350251.html

SOURCE Research and markets

Comments are closed.